These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8772700)

  • 1. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inner clot diffusion and permeation during fibrinolysis.
    Diamond SL; Anand S
    Biophys J; 1993 Dec; 65(6):2622-43. PubMed ID: 8312497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
    Wu JH; Siddiqui K; Diamond SL
    Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM; Popel AS; Alevriadou BR
    Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport.
    Anand S; Wu JH; Diamond SL
    Biotechnol Bioeng; 1995 Oct; 48(2):89-107. PubMed ID: 18623465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
    Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
    PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
    Anand S; Kudallur V; Pitman EB; Diamond SL
    Ann Biomed Eng; 1997; 25(6):964-74. PubMed ID: 9395042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
    Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
    Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
    Mutch NJ; Moore NR; Wang E; Booth NA
    J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke.
    Yang Y; Gu B; Xu XY
    Comput Biol Med; 2024 Mar; 171():108141. PubMed ID: 38367449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a multi-physics modelling framework for thrombolysis under the influence of blood flow.
    Piebalgs A; Xu XY
    J R Soc Interface; 2015 Dec; 12(113):20150949. PubMed ID: 26655469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.